Skip to main content

Amphastar Pharmaceuticals, Inc. (AMPH)

NASDAQ: AMPH · Delayed Price · USD
18.37 0.44 (2.45%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap882.34M
Revenue (ttm)384.04M
Net Income (ttm)10.45M
Shares Out47.73M
EPS (ttm)0.21
PE Ratio87.06
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume486,558
Open17.88
Previous Close17.93
Day's Range17.75 - 18.42
52-Week Range16.91 - 21.63
Beta0.74
AnalystsBuy
Price Target22.75 (+23.8%)
Est. Earnings DateNov 5, 2021

About AMPH

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone fo...

IndustryPharmaceuticals
IPO DateJun 25, 2014
CEOJack Zhang
Employees1,980
Stock ExchangeNASDAQ
Ticker SymbolAMPH
Full Company Profile

Financial Performance

In 2020, AMPH's revenue was $349.85 million, an increase of 8.53% compared to the previous year's $322.36 million. Earnings were $1.40 million, a decrease of -97.13%.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for AMPH stock is "Buy." The 12-month stock price forecast is 22.75, which is an increase of 23.84% from the latest price.

Price Target
$22.75
(23.84% upside)
Analyst Consensus: Buy

News

Amphastar Pharmaceuticals to Present at the Wells Fargo 2021 Virtual Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communicati...

2 weeks ago - Accesswire

3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 20...

Other symbols:BHCRDYTEVA
1 month ago - Zacks Investment Research

Amphastar Pharmaceuticals (AMPH) Meets Q2 Earnings Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 0.00% and 0.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2021

Reports Net Revenues of $101.7 Million for the Three Months Ended June 30, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 9, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Co...

1 month ago - Accesswire

Amphastar Pharmaceuticals (AMPH) to Report Q2 Results: Wall Street Expects Earnings Growth

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9th, 2021

RANCHO CUCAMONGA, CA / ACCESSWIRE / July 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2021 ended June 30, 2021, afte...

1 month ago - Accesswire

Amphastar Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference

RANCHO CUCAMONGA, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Commun...

3 months ago - GlobeNewsWire

Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

RANCHO CUCAMONGA, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communi...

3 months ago - GlobeNewsWire

Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary

RANCHO CUCAMONGA, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuti...

4 months ago - GlobeNewsWire

Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 42.11% and 6.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Recap: Amphastar Pharmaceuticals Q1 Earnings

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 58.82% over the past year to $0.27, whi...

4 months ago - Benzinga

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021

Reports Net Revenues of $103.0 Million for the Three Months Ended March 31, 2021

4 months ago - GlobeNewsWire

Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection

RANCHO CUCAMONGA, Calif., May 03, 2021 (GLOBE NEWSWIRE) --  Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company's Abbreviated...

4 months ago - GlobeNewsWire

Amphastar Pharmaceuticals (AMPH) to Report Q1 Results: Wall Street Expects Earnings Growth

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 2021

RANCHO CUCAMONGA, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2021 ended March 31, ...

4 months ago - GlobeNewsWire

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

Other symbols:BHCRDYTEVA
5 months ago - Zacks Investment Research

Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

RANCHO CUCAMONGA, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, T...

5 months ago - GlobeNewsWire

Why Humanigen, uniQure, bluebird bio, Amphastar Are Rallying Monday

Humanigen, Inc. (NASDAQ: HGEN), uniQure N.V. (NASDAQ: QURE), bluebird bio, Inc. (NASDAQ: BLUE) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) were among the biotech gainers on Monday.

Other symbols:BLUEHGENQURE
5 months ago - Benzinga

Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection

RANCHO CUCAMONGA, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company's Abbreviate...

5 months ago - GlobeNewsWire

New Strong Sell Stocks for March 18th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Other symbols:JAZZNSRGY
6 months ago - Zacks Investment Research

Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 14.29% and 7.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Recap: Amphastar Pharmaceuticals Q4 Earnings

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 128.57% year over year to $0.16, whic...

6 months ago - Benzinga

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020

Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020 Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020

6 months ago - GlobeNewsWire

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021

RANCHO CUCAMONGA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December ...

6 months ago - GlobeNewsWire

Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research